m+Medelevator.RU
← Поиск публикаций
Scientific reports · 2018

Genomic features of renal cell carcinoma with venous tumor thrombus.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Warsow Gregor, Hübschmann Daniel, Kleinheinz Kortine, Nientiedt Cathleen, Heller Martina, Van Coile Laura, Tolstov Yanis, Trennheuser Lukas, Wieczorek Kathrin, Pecqueux Carine, Gasch Claudia, Kuru Timur, Nyarangi-Dix Joanne, Hatiboglu Gencay, Teber Dogu, Perner Sven, Stenzinger Albrecht, Roth Wilfried, Hadaschik Boris, Pahernik Sascha, Jäger Dirk, Grüllich Carsten, Duensing Anette, Eils Roland, Schlesner Matthias, Sültmann Holger, Hohenfellner Markus, Duensing Stefan

Аннотация

A venous tumor thrombus (VTT) is a potentially lethal complication of renal cell carcinoma (RCC) but virtually nothing is known about the underlying natural history. Based on our observation that venous thrombi contain significant numbers of viable tumor cells, we applied multiregion whole exome sequencing to a total of 37 primary tumor and VTT samples including normal tissue specimens from five consecutive patients. Our findings demonstrate mutational heterogeneity between primary tumor and VTT with 106 of 483 genes (22%) harboring functional SNVs and/or indels altered in either primary tumor or thrombus. Reconstruction of the clonal phylogeny showed clustering of tumor samples and VTT samples, respectively, in the majority of tumors. However, no new subclones were detected suggesting that pre-existing subclones of the primary tumor drive VTT formation. Importantly, we found several lines of evidence for "BRCAness" in a subset of tumors. These included mutations in genes that confer "BRCAness", a mutational signature and an increase of small indels. Re-analysis of SNV calls from the TCGA KIRC-US cohort confirmed a high frequency of the "BRCAness" mutational signature AC3 in clear cell RCC. Our findings warrant further pre-clinical experiments and may lead to novel personalized therapies for RCC patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты